###### Strengths and limitations of this study

-   This is the first study to assess the quality of guidelines applicable to the pharmacological treatment of first-episode schizophrenia.

-   A multidisciplinary group identified key health questions that informed a clinically focused, systematic approach to data extraction to enhance the relevance for medicines optimisation.

-   Robust application of a validated tool (AGREE II) to assess the quality of clinical practice guidelines for the pharmacological treatment of first-episode schizophrenia.

-   A limitation of the study is that only guidelines written in English were included.

-   The application of the AGREE II instrument reflects the quality of guideline reporting which may not always indicate all information about how the guideline was developed.

Introduction {#s1}
============

Schizophrenia is a complex mental illness that has a significant impact on the individual and their families. The lifetime risk of schizophrenia is ∼1% and typically manifests in early adulthood.[@R1] The disorder is characterised by positive symptoms (such as delusions, hallucinations and disorganised speech), negative symptoms (such as social withdrawal and reduced motivation) and cognitive impairment.[@R2] Approximately three-quarters of people who have been diagnosed with schizophrenia will experience a relapse with about one-fifth going on to have long-term symptoms and disability.[@R1] [@R3] The life expectancy of people with schizophrenia is reduced by 15--20 years compared to those without severe mental ill health, only 8% are in employment and the cost to society in England is estimated at £11.8 billion per year.[@R4]

In recent years, there has been an increasing emphasis on early intervention for people experiencing psychotic symptoms and on the reduction of the duration of untreated psychosis.[@R5] Comprehensive programmes for the treatment of first-episode schizophrenia aim to promote recovery and improve quality of life and functional outcomes.[@R6] Antipsychotic medication is a key component of the treatment offered, but the clinical use of these medicines differs in the management of first-episode schizophrenia in comparison to a relapse or recurrence of an established illness.[@R7] At first presentation, a positive experience of using medication is likely to have long-term implications for adherence and outcome.[@R8]

Medicines optimisation is described by the National Institute for Health and Care Excellence (NICE) as a person-centred approach to safe and effective medicines use, to ensure that people obtain the best possible outcomes from their medicines.[@R9] To promote medicines optimisation, we must ensure that an individualised, evidence informed choice of medication is made available to service users.[@R9] Translating the best available evidence into practice is a challenge, so clinical practice guidelines (CPGs) are a useful summary of the most recent thinking in an area of clinical medicine. The Institute of Medicine describes CPGs as "statements that include recommendations intended to optimise patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options".[@R10] Guidelines and algorithms in mental healthcare can improve the quality of the services offered and the safety of medication use.[@R11] [@R12] Key health questions are used in guideline development processes to clarify the scope and purpose of the individual guideline.[@R13] [@R14] The definition of a set of clear and focused health questions will ensure that the recommendations are applicable to the clinical context in which the guideline is intended to be used.[@R14]

The quality of guidelines will have an impact on their applicability. The AGREE II tool has been used as a way of assessing the quality of guideline reporting in healthcare.[@R15] A systematic review and critical appraisal of guidelines for the treatment of schizophrenia was carried out by Gaebel *et al*[@R15] in 2005. At this time, Gaebel *et al* did not include the pharmacological treatment of first-episode schizophrenia when comparing the guidelines. Gaebel *et al*[@R16] updated this work in 2011 by reviewing the most recent versions of CPGs that were considered to be of good quality in 2005. Differences in treatment recommendations have been evaluated by various authors in relation to guidelines that apply to the USA,[@R19] or the difference in recommendations for single aspects of care such as maintenance treatment.[@R20] Since guidelines are updated or new guidelines become available, it is important to continue to assess their quality and understand how the growing evidence base has influenced recommendations.

The aim of this paper is to review the quality of CPGs and compare guideline recommendations to inform practice in the field of first-episode schizophrenia. We sought to do this by adopting a systematic approach to retrieving relevant guidelines; using AGREE II to assess the quality of guidelines; developing a list of key health questions relevant to the pharmacological treatment of first-episode schizophrenia and comparing guideline recommendations in relation to the key health questions identified.

Methodology {#s2}
===========

Data sources and search strategy {#s2a}
--------------------------------

The PubMed and EMBASE databases were searched for guidelines relating to the pharmacological treatment of first-episode schizophrenia (search terms described in online [supplementary material appendix](#SM1){ref-type="supplementary-material"} 1). A number of guideline repositories and specialist websites were searched for relevant guidelines. A manual search of reference lists for all identified guidelines was conducted. The initial search was conducted for guidelines published between January 2009 and April 2016.
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Inclusion and exclusion criteria {#s2b}
--------------------------------

Guidelines were included if they contained recommendations about the pharmacological treatment of adults experiencing a first episode of schizophrenia. A multidisciplinary group, compromised of consultant psychiatrists, pharmacists and nurses, with expertise in the care of people experiencing a first episode of schizophrenia, identified key clinical questions that a clinician would consider when taking an algorithmic approach to the use of medication for adults presenting with a first episode of schizophrenia ([box 1](#bx1){ref-type="boxed-text"}). These key questions then informed the selection of guidelines to be included in the analysis. Box 1Key health questions in an algorithmic approach to the pharmacological treatment of the positive symptoms of schizophrenia in adults presenting to an early intervention for psychosis serviceInitial presentation Which antipsychotic medications should be offered for the initial management of positive symptoms associated with a first episode of schizophrenia?What is the recommended dose of antipsychotic medications for first-episode schizophrenia?What is the duration of an initial trial of an antipsychotic for people experiencing a first episode of schizophrenia?Which antipsychotic medication should be considered when the person has not responded to the initial antipsychotic trialled?How long should a second antipsychotic trial last following non-response to the initial antipsychotic medication?Is there a role for long-acting injectable antipsychotic medications or depot antipsychotic formulations in the management of first-episode schizophrenia?When are combinations of antipsychotic medication an appropriate treatment strategy for people experiencing a first episode of schizophrenia?Maintenance of remission Which antipsychotic medication is recommended for the maintenance of remission from positive symptoms following a first episode of schizophrenia?What is the dose of maintenance antipsychotic medication following a first episode of psychosis?What is the duration of maintenance treatment following a first episode of schizophrenia?Can targeted intermittent treatment with antipsychotic medication be recommended in the management of first-episode schizophrenia?Treatment resistance When should clozapine be considered in the pharmacological management of first-episode schizophrenia?What is the recommended dose of clozapine?What is the recommended duration of a clozapine trial to adequately assess response?What strategies can be recommended for people who have had an inadequate response to clozapine treatment?

Guidelines were included if they were written in English, and made treatment recommendations based on a systematic review of the evidence in relation to adults aged 18 years or older. One reviewer (DK) did an initial screen of titles and abstracts to identify potentially eligible records. Two reviewers (DK and SMcW) then completed the second screen of abstracts to identify records that would undergo a full review. Where more than one record related to a single guideline development process, they were considered together.

Assessment of guideline quality {#s2c}
-------------------------------

The AGREE II instrument contains 23 items grouped into 6 domains: scope and purpose, stakeholder involvement, rigour of development, clarity and presentation, applicability and editorial independence.[@R13] The items are rated from 1 (strongly disagree) to 7 (strongly agree). Domain scores are then scaled between 0% and 100%. Following completion of the online AGREE II tutorial and practice exercise,[@R21] three reviewers (DK, SMcW, IS) independently applied the AGREE II criteria to each guideline. Domain scores were calculated based on the sum of all ratings within the domain and scaled by including the minimum possible score and the difference between the maximum and minimum possible scores for that domain.[@R21] The AGREE II score calculator from McMaster University was used to calculate the domain scores and assess inter-rater reliability.[@R22] A low level of discrepancy between raters (\<1.5 SDs from the mean domain score) was found for each of the six domains within each guideline. The raters used the domain scores to judge overall acceptability of the guidelines for the purpose of informing the pharmacological treatment of first-episode schizophrenia.

Comparison of guideline recommendations {#s2d}
---------------------------------------

Data in relation to guideline recommendations for the key health questions ([box 1](#bx1){ref-type="boxed-text"}) were extracted by one reviewer (DK) and then a second reviewer (CH) checked the accuracy of this work.

Results {#s3}
=======

Search and selection of guidelines {#s3a}
----------------------------------

The search strategy identified a total of 3299 records which were screened and yielded a final number of 10 guidelines for inclusion in the analysis ([figure 1](#BMJOPEN2016013881F1){ref-type="fig"}). The guidelines and their general characteristics are listed in [table 1](#BMJOPEN2016013881TB1){ref-type="table"}. The guideline from the World Journal for the Society of Biological Psychiatrists (WFSBP) is published in three parts but considered as one guideline.[@R23] The Royal Australia and New Zealand College of Psychiatrists (RANZCP) guideline[@R26] cross-references an Australian guide for the medical management of early psychosis,[@R27] and they are therefore considered together. The reasons for excluding guidelines included lack of documented development methodology, language other than English, that the guideline was entirely based on another guideline or that it did not address the pharmacological treatment of first-episode schizophrenia.

###### 

General characteristics of guidelines for the pharmacological treatment of first-episode schizophrenia

  Title                                                                                                                                                        Author/institution                                               Country                     Publication date         End of search date\*                                           Abbreviation and reference
  ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- --------------------------- ------------------------ -------------------------------------------------------------- ----------------------------
  The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements                                                           Schizophrenia Patient Outcomes Research Team                     USA                         December 2009            March 2008                                                     PORT[@R28]
  Clinical Practice Guidelines for Schizophrenia and Incipient Psychotic Disorder                                                                              Ministry of Health and Consumer Affairs                          Spain                       March 2009               July 2007                                                      Spain[@R29]
  Management of Schizophrenia in Adults                                                                                                                        Ministry of Health, Malaysia                                     Malaysia                    May 2009                 Not described                                                  Malaysia[@R30]
  Schizophrenia Clinical Practice Guidelines                                                                                                                   Ministry of Health, Singapore                                    Singapore                   April 2011               Not described                                                  Singapore[@R31]
  Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Clinical Psychopharmacology   British Association for Clinical Psychopharmacology              UK                          2011                     September 2008                                                 BAP[@R32]
  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia                                          World Federation of Societies of Biological Psychiatry (WFSBP)   International               May 2012 to March 2015   March 2012                                                     WFSBP[@R23]
  Management of Schizophrenia                                                                                                                                  Scottish Intercollegiate Guidelines Network                      Scotland                    March 2013               December 2011                                                  SIGN[@R3]
  The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on schizophrenia                                                      Harvard Medical School                                           USA                         January 2013             Not described. Paper submitted for publication December 2011   Harvard[@R33]
  Psychosis and schizophrenia in adults: treatment and management                                                                                              National Institute for Health and Care Excellence                UK                          February 2014            December 2008 (for pharmacologicalal treatment)                NICE[@R34]
  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders             Royal Australian and New Zealand College of Psychiatrists        Australia and New Zealand   2014 and 2016            Not described                                                  RANZCP[@R26] [@R27]

\*Final search date of the systematic review of evidence that informed the guideline development process.

![PRISMA diagram describing process of guideline selection.](bmjopen2016013881f01){#BMJOPEN2016013881F1}

Assessment of guideline quality {#s3b}
-------------------------------

The standardised domain scores for each CPG are detailed in [table 2](#BMJOPEN2016013881TB2){ref-type="table"}. The domain scores for 'scope and purpose' were generally high with all but one guideline,[@R33] scoring \>80% (range 50--100%). There was wider variation among domain scores for stakeholder involvement, ranging from 20% to 90%. The reporting of development methodology as assessed by the 'rigor of development' domain was of variable quality with a range of 41% to 91%. In the domain 'clarity of presentation', CPGs generally scored well (range 52% to 96%) in contrast to the 'applicability' domain which had wide variability (14% to 79%). The reporting of 'editorial independence' in CPGs was scored between 25% and 97%. The guidelines selected were generally of good quality with three guidelines recommended for use as written, six guidelines acceptable with modifications and one not recommended. All reviewers were in agreement with the overall guideline acceptability.

###### 

Domain scores for CPGs addressing the pharmacological treatment of first-episode schizophrenia using AGREE II as assessed by three raters and scaled as a percentage of the maximum possible score for each domain

  Domain                    PORT (%)   Spain (%)   Malaysia (%)   Singapore (%)   BAP (%)   WFSBP (%)   SIGN (%)   Harvard (%)   NICE (%)   RANZCP (%)
  ------------------------- ---------- ----------- -------------- --------------- --------- ----------- ---------- ------------- ---------- ------------
  Scope and purpose         85         85          100            96              93        83          96         50            100        81
  Stakeholder involvement   54         80          93             75              63        44          90         20            89         67
  Rigour of development     69         82          74             41              56        61          91         57            84         49
  Clarity of presentation   85         89          94             94              83        52          96         78            94         83
  Applicability             29         57          39             40              38        21          79         14            75         31
  Editorial independence    78         75          97             25              39        64          78         86            86         42
  Overall assessment        Y          Y           Y/M            N               Y/M       Y/M         Y          Y/M           Y          Y/M

N, guideline is not recommended; Y, guideline is recommended for use; Y/M, guideline is acceptable with modifications.

BAP, British Association of Psychopharmacology; CPG, clinical practice guidelines; NICE, National Institute of Clinical and Care Excellence; PORT, Patient Outcomes Research Team; RANCP, Royal Australian and New Zealand College of Psychiatrists; SIGN, Scottish Intercollegiate Guidelines Network; WFSBP, World Federation of Societies of Biological Psychiatry.

Comparison of CPG content {#s3c}
-------------------------

### Rating the quality of evidence used to support recommendations {#s3c1}

Guideline development groups had a range of approaches to rating the quality of the evidence and grading the strength of related recommendations. The methodologies used are listed in the supplemental material (see online [supplementary material, appendix 2](#SM2){ref-type="supplementary-material"}). One CPG did not describe a method for grading evidence.[@R33] PORT took a very direct approach of needing two randomised controlled trials (RCTs) as the minimum level of evidence required to make a recommendation.[@R28] NICE requires the reader to understand the language used within the recommendations to interpret the strength of the recommendation.[@R34] Other groups used methods of varying detail and complexity to describe the strength of evidence.[@R3] [@R23] [@R26] [@R29]
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### Recommendations in relation to key health questions at initial presentation {#s3c2}

A table comparing the recommendation from CPGs in relation to key health questions is available in online [supplementary material appendix 3](#SM3){ref-type="supplementary-material"}. Guidelines broadly agree that all antipsychotics are equally effective for the treatment of positive symptoms in first-episode schizophrenia.[@R3] [@R23] [@R26] [@R28] There is also a consensus that the most important consideration when helping a person make a decision about pharmacological treatment is the side effect profile of the antipsychotic.[@R3] [@R23] [@R26] [@R28] Five guidelines recommend second-generation antipsychotic (SGA) medications as the preferred initial choice because of the view that the side effect profiles of this group of medicines are more favourable.[@R23] [@R26] [@R29] [@R30] [@R33] Olanzapine is specifically excluded as a recommended initial choice of antipsychotic medication from PORT,[@R28] Harvard[@R33] and RANZCP,[@R26] because of the issue of metabolic side effects and weight gain. Harvard uses the additional consideration of efficacy in the maintenance phase of treatment in excluding quetiapine because of a poorer evidence base for maintenance of remission.[@R33] All guideline development groups consider the evidence for the use of antipsychotic medications for first-episode schizophrenia to be of high quality even though not all antipsychotic medications have been tested in this cohort of patients. For example, WFSBP notes that haloperidol is the only first-generation antipsychotic (FGA) that has actually been used in trials in first-episode schizophrenia.[@R23] Spain,[@R29] and RANZCP,[@R26] recommend an antipsychotic free assessment period using benzodiazepines to help alleviate distress.
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The most common recommendation for the duration of an initial trial of antipsychotic medication is 4 weeks.[@R29] [@R31] Evidence that the majority of the benefit seen with antipsychotic medication will be apparent in the first two weeks of treatment is reflected in the potentially shorter trial period suggested by some guidelines.[@R3] [@R23] [@R26] There is consensus regarding the lowest effective dose being used with a number of guidelines offering suggestions for FGA and SGA doses specific to the first episode of schizophrenia.[@R23] [@R26] [@R28] [@R33] The only exception to this dose recommendation is that of quetiapine, which requires a dose similar to that used in acute relapse based on the interpretation of the European First Episode Study[@R35] trial by PORT.[@R28]

Oral medication is recommended with parenteral formulations reserved for those who prefer this route of administration or when poor adherence is a clinical priority.[@R3] [@R23] [@R26] [@R28] While monotherapy is ideal, there is recognition that combinations of antipsychotic medication may be useful in certain scenarios such as clozapine augmentation.[@R3] [@R23] [@R26] [@R28]

### Recommendations in relation to key health questions regarding the maintenance of remission following a first episode of schizophrenia {#s3c3}

Recommendations regarding the duration of maintenance treatment following a first episode of schizophrenia vary between 1 and 2 years,[@R3] [@R24] [@R26] [@R29] [@R30] [@R34] with some guideline development groups failing to make any recommendation.[@R28] [@R31] RANZCP considers engagement with a first-episode schizophrenia service for up to 5 years to be beneficial.[@R26] The antipsychotic medication used for relapse prevention is generally the antipsychotic used in the acute management of symptoms at the dose that was effective in the acute phase.[@R3] [@R24] [@R28] [@R33] Evidence for the superiority of medications such as olanzapine and risperidone, or inferiority of quetiapine in relapse prevention, is reflected in the recommendations of some guidelines.[@R3] [@R24] [@R33] Targeted, intermittent treatment is a potential strategy that reduces side effect burden and the need for adherence to longer term medication use. The evidence, however, does not support this approach because of the increased risk of relapse in comparison to continuous treatment.[@R24] [@R28] [@R32] [@R34]

### Recommendations in relation to key health questions regarding treatment-resistant schizophrenia {#s3c4}

There is consensus that the definition of treatment resistance is the failure of two trials of antipsychotic medication at optimal dose for an adequate period of time.[@R3] [@R23] [@R26] [@R28] Before making a diagnosis of treatment resistance, additional considerations include comorbid substance misuse and an assessment of treatment adherence. The interpretation of recent evidence regarding the efficacy of antipsychotic medication[@R36] points to the trial of olanzapine, risperidone or amisulpride as one of the two antipsychotics used before a trial of clozapine is considered.[@R3] [@R33] Clozapine is universally recommended as the treatment of choice for treatment-resistant schizophrenia. The variation in doses suggested reflect the individuality of clozapine use in clinical practice,[@R24] [@R28] [@R29] [@R31] with the potential for delayed response to clozapine treatment leading to the longer duration of a trial of clozapine of up to 1 year recommended in some guidelines.[@R26] [@R28] [@R29] [@R32] The most common strategy suggested when there has been a partial response to clozapine despite dose optimisation is to combine clozapine with a second antipsychotic taking additional side effect profile and pharmacology into consideration.[@R3] [@R24] [@R26] [@R29] Lamotrigine is also considered by some CPGs to have sufficient evidence to recommend its use as a clozapine augmentation strategy.[@R3] [@R24] [@R33] There is very little evidence to guide treatment options for those who do not have adequate symptom reduction despite clozapine augmentation.[@R24] [@R30] [@R31] [@R33]

Discussion {#s4}
==========

Assessment of guideline quality {#s4a}
-------------------------------

This systematic review identified 10 CPGs addressing the pharmacological management of first-episode schizophrenia which were assessed using the AGREE II instrument. The NICE, SIGN and Spanish guidelines scored best across all domains.[@R3] [@R29] [@R34] The CPGs assessed were generally well presented with specific statements describing the scope and purpose of each guideline. The 'rigor of development' scores for each guideline reflected the quality of methodological reporting within the text of the guideline. Plans to update the guidelines were documented for six of the CPGs.[@R3] [@R28] [@R34] Updates are currently due for two guidelines.[@R29] [@R30] The majority of recommendations regarding the pharmacological treatment of first-episode schizophrenia in the NICE guidelines have not been updated since the 2009 version of the CPG.[@R34] In most guidelines, there is significant cross-referencing of other similar guidelines.[@R3] [@R23] [@R29] SIGN and Malaysia used the NICE evidence base as their foundation.[@R3] [@R30] This would appear reasonable as the NICE guideline was considered of very high quality in Gaebel *et al\'s*[@R15] systematic review.

Guidelines were generally weakest in the applicability domain with little offered by way of support for implementation. Examples of tools used to support applicability included versions of the CPG for service users,[@R3] [@R29] [@R34] algorithms[@R26] [@R29] [@R33] [@R34] and quality indicators.[@R30] [@R34] The inclusion of tools such as decision aids in guidelines may improve their applicability and make a collaborative approach to care more feasible in clinical practice.[@R37] [@R38] Overall assessment of quality was lowest for guidelines produced by specialist organisations, where limited stakeholder involvement added to poor applicability,[@R23] [@R32] [@R33] or the reporting of development methodology was limited.[@R23] [@R26] [@R33] Within the evidence base itself, publication bias is an important consideration.[@R39] [@R40] CPGs such as NICE and SIGN make significant efforts to measure the risk of bias in original trials.[@R3] [@R34] Response and remission are not well defined in the guidelines even though some recommend using rating scales to assess same.

Evidence-based recommendations are drawn up following an evaluation of available research and ranked according to the strength of the supporting evidence. Consensus-based recommendations are derived from the practical experience of the guideline developers. This methodology allows for the development of recommendations for clinical scenarios where the published evidence is weak or the evidence does not reflect the patient characteristics of everyday clinical practice.[@R41] While the 'rigor of development' domain scores may be excellent in an AGREE assessment, the specificity of the subsequent recommendations vary. NICE emphasises that each treatment phase be considered an individual therapeutic trial and that this will encompass any new evidence that is published in relation to pharmacological approaches.[@R34] In contrast, the WFSBP guideline evaluates the evidence in relation to each antipsychotic medication and Harvard makes more specific recommendations regarding the choice of antipsychotic medication.[@R23] [@R33] It is clear from the levels of evidence used to make recommendations in CPGs that the available research is not comprehensive enough to address all key health questions relevant to the pharmacological treatment of first-episode schizophrenia. It is therefore reasonable to accept a transparent, consensus-based approach so that the reader can also take a view on the topic.

Clinical significance {#s4b}
---------------------

Early intervention for those experiencing their first episode of schizophrenia has the potential to improve outcomes and is an important area of current research.[@R42] Early intervention services provide a range of pharmacological, psychological and educational interventions with the aims of symptom remission and functional recovery with respect to personal, employment, educational and social outcomes.[@R46] Antipsychotic medication is a key component of care.[@R6] The clinical use of medication differs in this cohort of patients, who tend to be more sensitive to the effects of antipsychotic medication and more vulnerable to adverse effects than those in later phases of the illness.[@R35] Specific guidelines that address the key health questions relevant to the pharmacological treatment of first-episode schizophrenia are therefore required.

Navigating the varying side effect profiles of individual antipsychotic medicines has become the clinical priority when choosing the most appropriate medication in first-episode schizophrenia. Adverse effects have a significant impact on quality of life and adherence to medication,[@R47] [@R48] and this must be balanced against the fact that residual symptoms also have an impact on quality of life.[@R49] Research among those experiencing their first episode of schizophrenia demonstrated the increased sensitivity to metabolic side effects of SGAs without greater efficacy when compared to FGAs.[@R35] [@R50] The risk of long-term neurological side effects such as tardive dyskinesia with FGAs has led to a consensus among some guideline development groups that SGAs are preferable in first-episode schizophrenia.[@R23] [@R26] [@R29] [@R30] [@R33] Where FGAs are chosen, low potency FGAs such as chlorpromazine are preferred.[@R3] [@R23] [@R32] Guidelines that relegate olanzapine to second-line treatment do so because of the relatively high risk of metabolic side effects and weight gain in particular.[@R26] [@R28] [@R33] An antipsychotic free assessment period is recommended by two CPGs, presumably to allow for a clear picture of symptoms to be obtained at baseline.[@R26] [@R29] However, the feasibility of implementing this recommendation depends on ease of access to specialised assessments for first-episode schizophrenia and it may not be reasonable to delay treatment.

Approximately 20% of those who meet the diagnostic criteria for a first episode of schizophrenia will not go on to experience any subsequent episodes.[@R1] The optimal duration of treatment following a first episode of schizophrenia is therefore an important health question. In one recent study, the relapse rate for those who discontinued medication following 18 months of treatment (and were in clinical remission for more than 12 months with 6 months or more of functional recovery) was twice that of those who continued maintenance antipsychotic medication over the 3-year study period.[@R51] There is evidence of benefit for service users who remain in contact with an early intervention service for up to 5 years compared to those who do not.[@R42] Wunderink *et al*[@R52] have suggested shorter periods of antipsychotic use, arguing that despite reoccurrence of symptoms, quality of life at 7-year follow-up was better for those who had discontinued medication at 6 months than those who received maintenance antipsychotic medication. These findings have not been replicated and current practice supports maintenance treatment with informed choices to be made at an individual level regarding continuation of antipsychotic medication at ∼2 years following symptom remission of the first episode.[@R53]

Evaluations of the efficacy of antipsychotic medication have not demonstrated superiority for any individual agent for those experiencing a first episode of schizophrenia,[@R34] with response rates between 40% and 90%.[@R54] Clozapine, for example, is no more effective than chlorpromazine as initial treatment.[@R55] Response rates to subsequent trials of antipsychotic medications other than clozapine are poor.[@R56] Recent evidence suggests that there may be some efficacy benefit for individual SGAs in the acute phase of established recurrent schizophrenia[@R36] and for maintenance of remission.[@R57] This evidence has been interpreted in guidelines by suggesting that risperidone, olanzapine or amisulpride should be used as one of the two antipsychotics recommended before a trial of clozapine is considered.[@R3] [@R33] While oral medication is recommended in CPGs, there is increasing interest in the use of long-acting antipsychotic injections early in schizophrenia treatment because of the potential to detect non-adherence early, reduce relapse and improve psychosocial functioning.[@R58]

Clozapine is universally accepted by guideline development groups as the antipsychotic of choice for treatment-resistant schizophrenia. Approximately 60% of those who are considered treatment-resistant will respond to clozapine.[@R59] Leucht *et al\'s*[@R36] analysis of the efficacy of antipsychotic medication in the acute phase of multiepisode schizophrenia showed the relative benefit of clozapine. The use of clozapine is supported by open label studies, cohort studies and database studies with important positive outcomes such as reduced hospitalisation.[@R60] However, in a recent multivariate meta-analysis of randomised controlled trials comparing clozapine and other antipsychotic medication, the Cochrane Collaboration failed to find any significant efficacy difference in treatment-resistant schizophrenia.[@R63] The authors highlighted the many limitations of RCTs in the area of treatment resistance including varying definitions of treatment resistance. Differing doses of antipsychotics and the difficulty of blinding to clozapine treatment. Given the benefits of clozapine for treatment-resistant schizophrenia and the importance of early effective treatment for those experiencing a first episode of schizophrenia, it has been argued that clozapine should be considered earlier in the treatment algorithm as a second-line option.[@R54]

CPGs are not intended to dictate all aspects of care for patients. Individual factors such as personal preferences, comorbidity, concurrent medications and previous experience with medication will have an impact on the choices made. Although guidelines and algorithms in mental healthcare can improve the quality of medication use,[@R11] [@R12] CPGs are not always used in practice[@R64] and implementation strategies do not always result in improved adherence to guideline recommendations.[@R67] In the Recovery After an Initial Schizophrenia Episode (RAISE) study, the authors identified 39% of the sample who could have benefited from a medication review because prescribing practices were not in line with current guidelines in the USA.[@R68] For example, the use of olanzapine was relatively high, even though it is specifically not recommended in a first episode of schizophrenia by the PORT guidelines. The UK National Audit of Schizophrenia examined the implementation of NICE guidelines. While most of the sample of 5608 patients were receiving pharmacological treatment in line with the guideline, 11% were prescribed two or more antipsychotic medications and 10% were prescribed doses above the recommended limits.[@R69] Despite the importance placed on early use of clozapine in CPGs, evidence suggests it is under-prescribed with many different strategies being used before clozapine is offered.[@R70] [@R71] Clozapine\'s effectiveness may diminish if used later in the illness, making it vitally important to identify treatment resistance and manage it appropriately as early as possible.[@R72] Within the setting of an early intervention service, it may be feasible to implement guidelines more effectively when they are relevant to those experiencing a first episode of schizophrenia, are facilitated by local buy-in and reflect a multidisciplinary approach.[@R64]

Strengths and limitations {#s4c}
-------------------------

The clinical use of antipsychotic medication as part of the early intervention model of service delivery is an important topic of current research. A strength of this study is the identification of key health questions that are relevant to clinical practice and the comparison of guideline recommendations in relation to these key health questions. The AGREE II tool has been extensively used to evaluate the quality of CPGs in many aspects of clinical care including psychiatry.[@R15] [@R17] [@R18] Using the AGREE II tool helps to identify guidelines that have a transparent, systematic method of development. For services that are not bound by national guidelines, this work could inform the development of local guidelines using methodology such as the ADAPTE process.[@R14]

The AGREE II tool does not evaluate the quality of the evidence that was used to formulate the recommendations. The subjectivity inherent in the application of the AGREE II tool is reduced by the independent scoring of CPGs by three raters and by further measuring any marked discrepancy between scores. While every effort was made to include all relevant guidelines for the treatment of first-episode schizophrenia, it is possible that some have been inadvertently excluded. We only included guidelines written in the English language. Many of the guidelines included were published more than 5 years ago and could therefore be considered out of date.[@R10] A comparison of CPG content would ideally involve taking the various methods by which quality of evidence is evaluated and grouping them into one standard method.[@R14] The AGREE tool includes an assessment of bias in relation to statements of conflict of interest for those involved in guideline development and stakeholder involvement. Even if conflicts of interest were declared, it was difficult to ascertain how this was managed and how it influenced final recommendations.[@R73] The Grading of Recommendations Assessment, Development and Evaluation working group has developed an Evidence to Decision framework for CPGs that has the potential to ensure a structured, transparent approach to developing CPG recommendations.[@R74]

Conclusions {#s5}
===========

The aims of early intervention for those experiencing a first episode of schizophrenia are to reduce symptoms and improve outcomes. Optimal use of antipsychotic medication is critical and clinical practice differs for the first-episode cohort in comparison to those experiencing multiepisode schizophrenia. CPGs can guide medicines optimisation, but it is important for the target users to assess the quality of CPGs so that they can have confidence in the recommendations made. The AGREE II instrument is a useful way of structuring this assessment. CPGs of good methodological quality for the pharmacological treatment of first-episode schizophrenia exist but deficiencies in the evidence base make it difficult to address the key health questions relevant to medicines optimisation in clinical practice. Further research is required to guide choice and dose of medication, duration of treatment and the management of treatment resistance.
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